The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Fentanyl citrate (Breakyl®) has been rejected for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. The manufacturer failed to make a submission.
Saxagliptin / Metformin (Kombogylze®) has been accepted for use in the treatment of type 2 diabetes mellitus in adults as triple oral therapy (in combination with a sulphonylurea) to improve glycaemic control when dual therapy (with metformin and a sulphonylurea), in combination with diet and exercise, does not provide adequate glycaemic control.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Soluble drug formulations associated with increased CV events||MTRAC Reviews - January 2014 »|